Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4532990 in Alcohol-related Liver Disease (STARLIGHT)
NCT06613698Phase 2Recruiting
- Sponsor
- GSK
- Start
- Sep 2024
- Primary completion
- Nov 2027
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 18
01
Overview
A Phase 2 trial of GSK4532990 in alcoholic liver disease (ALD), sponsored by GSK. Started Sep 2024; status: recruiting.
02
Drugs
GSK4532990
03
Conditions
alcoholic liver disease (ALD)
Beyond the preview
Go deeper on NCT06613698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613698.